- Home
- ABUS vs ASIX Comparison
ABUS vs ASIX Comparison
Compare ABUS & ASIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ASIX
- Stock Information
- Founded
- ABUS 2005
- ASIX 2016
- Country
- ABUS United States
- ASIX United States
- Employees
- ABUS N/A
- ASIX N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ASIX Major Chemicals
- Sector
- ABUS Health Care
- ASIX Industrials
- Exchange
- ABUS Nasdaq
- ASIX Nasdaq
- Market Cap
- ABUS 672.1M
- ASIX 663.1M
- IPO Year
- ABUS N/A
- ASIX N/A
- Fundamental
- Price
- ABUS $3.08
- ASIX $23.51
- Analyst Decision
- ABUS Strong Buy
- ASIX Hold
- Analyst Count
- ABUS 4
- ASIX 1
- Target Price
- ABUS $5.50
- ASIX $26.00
- AVG Volume (30 Days)
- ABUS 827.5K
- ASIX 231.2K
- Earning Date
- ABUS 05-14-2025
- ASIX 05-02-2025
- Dividend Yield
- ABUS N/A
- ASIX 2.72%
- EPS Growth
- ABUS N/A
- ASIX 3682.26
- EPS
- ABUS N/A
- ASIX 3.11
- Revenue
- ABUS $6,403,000.00
- ASIX $1,558,519,000.00
- Revenue This Year
- ABUS $14.57
- ASIX $6.75
- Revenue Next Year
- ABUS $15.84
- ASIX $5.06
- P/E Ratio
- ABUS N/A
- ASIX $7.47
- Revenue Growth
- ABUS N/A
- ASIX 6.03
- 52 Week Low
- ABUS $2.63
- ASIX $18.44
- 52 Week High
- ABUS $4.72
- ASIX $33.00
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- ASIX 59.14
- Support Level
- ABUS $2.94
- ASIX $23.00
- Resistance Level
- ABUS $3.42
- ASIX $24.93
- Average True Range (ATR)
- ABUS 0.18
- ASIX 0.77
- MACD
- ABUS -0.04
- ASIX 0.23
- Stochastic Oscillator
- ABUS 17.72
- ASIX 67.73
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.